Join
Live feed
·
PRReleasevia Quantisnow
Clearside Biomedical Inc. logo

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

ByQuantisnow·Wall Street's wire, on your screen.
CLSD· Clearside Biomedical Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLSD (Clearside Biomedical Inc.) and more on Quantisnow.